Skip to main content

Table 3 Association between HR status of first breast cancer and CBC risk, by time since diagnosis

From: Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population

  Time <5 years to CBC Time 5 to <10 years to CBC Time ≥10 years to CBC  
N (cases/controls) RRa (95% CI) N (cases/controls) RRa (95% CI) N (cases/controls) RRa (95% CI) P-heterogeneity
All women, tumor status at first diagnosis
 ER status
  Positive 306/585 1.0 (ref.) 293/440 1.0 (ref.) 198/229 1.0 (ref.)  
  Negative 186/241 1.4 (1.1, 1.9) 186/209 1.3 (1.0, 1.8) 95/111 1.0 (0.7, 1.5) 0.37
  Other/unknownb 94/160   95/155   68/82   
 PR status
  Positive 262/477 1.0 (ref.) 249/395 1.0 (ref.) 176/211 1.0 (ref.)  
  Negative 183/238 1.3 (1.0, 1.8) 169/203 1.3 (1.0, 1.8) 90/108 0.9 (0.6, 1.4) 0.26
  Other/unknownb 141/271   156/206   95/103   
 Joint ER/PR status
  ER+/PR+ 239/423 1.0 (ref.) 219/351 1.0 (ref.) 163/184 1.0 (ref.)  
  ER+/PR- 38/68 1.0 (0.6, 1.6) 31/48 1.2 (0.7, 2.2) 16/26 0.6 (0.3, 1.3)  
  ER-/PR- 145/166 1.5 (1.1, 2.1) 136/145 1.5 (1.0, 2.0) 71/76 1.1 (0.7, 1.6) 0.45
  Other/unknownb,c 164/329   188/260   111/136   
Women who did not receive tamoxifen treatment for first diagnosis, tumor status at first diagnosis
 ER status
  Positive 169/290 1.0 (ref.) 141/196 1.0 (ref.) 97/108 1.0 (ref.)  
  Negative 169/212 1.4 (0.9, 2.1) 166/173 1.4 (0.9, 2.0) 87/92 1.1 (0.7, 1.9) 0.77
  Other/unknownb 85/142   80/135   60/77   
 PR status
  Positive 135/222 1.0 (ref.) 117/165 1.0 (ref.) 84/102 1.0 (ref.)  
  Negative 159/187 1.4 (0.9, 2.1) 145/160 1.3 (0.8, 2.0) 82/82 1.3 (0.7, 2.2) 0.97
  Other/unknownb 129/235   125/179   78/93   
 Joint ER/PR status
  ER+/PR+ 121/185 1.0 (ref.) 97/136 1.0 (ref.) 75/83 1.0 (ref.)  
  ER+/PR- 24/31 1.3 (0.6, 2.7) 16/26 0.7 (0.3, 2.0) 12/13 1.6 (0.4, 6.2)  
  ER-/PR- 135/152 1.4 (0.9, 2.3) 127/125 1.5 (0.9, 2.4) 67/64 1.3 (0.7, 2.4) 0.84
  Other/unknownb,c 143/276   147/217   90/117   
  1. Abbreviations: HR hormone receptor, CBC contralateral breast cancer, RR risk ratio, CI confidence interval, N number, ER estrogen receptor, PR progesterone receptor
  2. aAdjusted for age at first breast cancer diagnosis, first-degree family history of breast cancer, histologic assessment, stage, menopausal status, age at menarche, parity, radiation, chemotherapy and hormone therapy at first breast cancer diagnosis. b“Other/unknown” category consists of women for whom no laboratory test was given, the test was given and the results were unknown or the test was given and the results were borderline; estimates not reported. cIncludes tumors classified as ER-/PR+